who suggested in a research note that the add-on effect of efti on Keytruda is impressive. “Efti+pembro may provide a chemo-free option with similar (close enough) response rates as chemo ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Enfortumab vedotin is marketed as Padcev (Astellas), and pembrolizumab is marketed as Keytruda (Merck). The combination, Powles said, “has doubled median progression-free survival and overall ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

Merck stock tumbled Monday after Summit Therapeutics' cancer drug outperformed blockbuster Keytruda in a study of lung cancer ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major pathological response in patients with resectable locally advanced head and ...